Biomarker Core
$609,280P01FY2011HLNIH
Stanford University, Stanford CA
Investigators
Linked publications & trials
Paper 39209474Paper 39209468Paper 38471030Paper 38085642Paper 37989727Paper 37934691Paper 36744494Paper 35696338Paper 34872889Paper 34215862Paper 34181952Paper 33952674Paper 33839076Paper 33651671Paper 33548142Paper 33334941Paper 33294774Paper 33044226Paper 32763154Paper 32602650Paper 32382044Paper 31988495Paper 31980301Paper 31917512Paper 31798835Paper 31513751Paper 31094755Paper 30806154Paper 30661465Paper 30635853Paper 30586708Paper 30582451Paper 30545975Paper 30545970Paper 30131961Paper 29894205Paper 29877097Paper 29767574Paper 29545367Paper 29467298Paper 29369345Paper 28935667Paper 28934596Paper 28469087Paper 27804215Paper 26967995Paper 26873944Paper 26177174Paper 25981508Paper 25888148Paper 25853696Paper 25727073Paper 25539853Paper 24951765Paper 24880953Paper 24684441Paper 24612731Paper 24570092Paper 24569371Paper 24468195Paper 24446489Paper 24355640Paper 24267896Paper 24161166Paper 24158514Paper 24155924Paper 24051955Paper 23986401Paper 23867624Paper 23797537Paper 23769046Paper 23530212Paper 23402031Paper 23400799Paper 23372927Paper 23202738Paper 23102413Paper 23002078Paper 22990707Paper 22842496Paper 22743666Paper 22683569Paper 22307907Paper 22185646Paper 21998328Paper 21868697Paper 21821917Paper 21763677Paper 21606594Paper 21562133
Abstract
This Core coordinates patient enrollment, organizes clinical data, and standardizes collection of clinical specimens and bioassays. In so doing, the Core will leverage the large cohorts of patients with Pulmonary Arterial Hypertension (PAH), at risk for Ventilator Induced Injury of the Newborn Lung (VIINL) or chronic lung disease (CLD) and candidates for Lung Transplantation (LT) followed at the Stanford. They will carry out an established platform of state-of-the-art bioassays for cells and fluids that will be related to physiological endpoints that reflect disease severity.
View original record on NIH RePORTER →